MP28-19 A SURVEY OF EXPOSURE TO THE USE OF XIAFLEX FOR THE TREATMENT OF PEYRONIE’S DISEASE AMONG UNITED STATES UROLOGY RESIDENCY PROGRAMS

作者：Justin Loloi, Kyle Schuppe, Raghuram Reddy, Farah Rahman, Ari Bernstein, Pritika Reddy, Nikhil Kulkarni, Thomas A. Masterson, Ranjith Ramasamy · 发表于：The Journal of Urology · 年份：2024 · DOI：10.1097/01.ju.0001008872.42208.7a.19 · 研究领域：Sexual function and dysfunction studies、Pelvic floor disorders treatments、Urinary Bladder and Prostate Research

You have accessJournal of UrologySexual Function/Dysfunction: Peyronie's Disease (MP28)1 May 2024MP28-19 A SURVEY OF EXPOSURE TO THE USE OF XIAFLEX FOR THE TREATMENT OF PEYRONIE'S DISEASE AMONG UNITED STATES UROLOGY RESIDENCY PROGRAMS Justin Loloi, Kyle Schuppe, Raghuram V. Reddy, Farah Rahman, Ari Bernstein, Pritika Reddy, Nikhil Kulkarni, Thomas Masterson, and Ranjith Ramasamy Justin LoloiJustin Loloi , Kyle SchuppeKyle Schuppe , Raghuram V. ReddyRaghuram V. Reddy , Farah RahmanFarah Rahman , Ari BernsteinAri Bernstein , Pritika ReddyPritika Reddy , Nikhil KulkarniNikhil Kulkarni , Thomas MastersonThomas Masterson , and Ranjith RamasamyRanjith Ramasamy View All Author Informationhttps://doi.org/10.1097/01.JU.0001008872.42208.7a.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Xiaflex® (Collagenase Clostridium Histolyticum) is an FDA-approved treatment for patients with Peyronie's Disease. Despite its approval and widespread implementation in clinical practice, there is concern that urologists in training are offered minimal exposure to its use. Thus, the purpose of this study was to evaluate the exposure of urology residents to Peyronie's Disease and its management, particularly Xiaflex®. METHODS: A three-question Google Forms survey regarding exposure of residents to Peyronie's Disease and the Use of Xiaflex® was created and disseminated through email to urology resi...